COMPARISON OF TOPICAL CAPSAICIN AND TOPICAL TURPENTINE OIL FOR TREATMENT OF PAINFUL DIABETIC NEUROPATHY
Abstract
Background: Diabetes Mellitus is a pandemic of the modern era owing to our rapidly deteriorating lifestyle. Painful diabetic neuropathy is one of the costliest and disabling complications of diabetes mellitus. No single treatment exists to prevent or reverse neuropathic changes or to provide total pain relief. Topical Capsaicin and Turpentine Oil are found to be effective in treatment of painful diabetic neuropathy. Methods: Patients of either gender with ages between 18 and 70 years having painful diabetic neuropathy already taking one oral drug for painful neuropathy and treatment for diabetes mellitus and an HbA1C less than 8.5% were included while Pregnant or lactating mothers, patients with chronic liver disease and patients with renal insufficiency (creatinine >3.0 mg/dl) and peripheral arterial disease were excluded from study. Patients were randomly divided into two groups (A & B) using computer generated random number table. Group A was given topical application of capsaicin while Group B was given topical application of commercially available turpentine oil over painful site on feet. Results: 300 patients were equally divided in two groups. The patients in group A had a Visual Analog Pain Score of 7.91±5.10 at baseline and 5.10±1.343 after 3 months of treatment (p-value 0.0001). The patients in group B had a Visual Analog Pain Score of 7.83±1.012 at baseline and 5.20±1.187 after 3 months of treatment (p-value 0.0001). Chi Square test was applied to compare efficacy of both groups. It was noted that 71 (53%) had efficacy in group A and 63 (47%) had efficacy in the group B but the difference was not statistically significant. (p-value=0.399). Conclusion: It has been concluded that turpentine oil is effective in managing diabetic neuropathic pain similar to capsaicin cream. Keywords: Diabetes Mellitus; Painful diabetic neuropathy; Capsaicin; Turpentine oilReferences
Hu FB. Globalization of Diabetes. Diabetes Care 2011;34(6):1249–57.
WHO. Global report on diabetes. World Health Organization, Geneva; 2016.
Ali A, Iqbal F, Taj A, Iqbal Z, Amin MJ, Iqbal QZ. Prevalence of microvascular complications in newly diagnosed patients with type 2 diabetes. Pak J Med Sci 2013;29(4):899–902.
Hayes A, Arima H, Woodward M, Chalmers J, Poulter N, Hamet P, et al. Changes in Quality of Life Associated with Complications of Diabetes: Results from the ADVANCE Study. Value Health 2016;19(1):36–41.
Peltier A, Goutman SA, Callaghan BC. Painful diabetic neuropathy. BMJ 2014;348:g1799.
Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and Characteristics of Painful Diabetic Neuropathy in a Large Community-Based Diabetic Population in the U.K. Diabetes Care 2011;34(10):2220–4.
Aslam A, Singh J, Rajbhandari S. Pathogenesis of Painful Diabetic Neuropathy. Pain Res Treat 2014;2014:412041.
Javed S, Petropoulos IN, Alam U, Malik RA. Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis 2015;6(1):15–28.
Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 2011;107(4):490–502.
Department of health and human services. Food and drug administration. [Internet]. [cited 2016 Aug 4]. Available from: http://www.fda.gov/OHRMS/DOCKETS/98fr/060403b.htm
Web Med. Find a Vitamin or supplement: TURPENTINE OIL. [Internet]. [cited 2016 Aug 4]. Available from: http://www.webmd.com/vitamins-supplements/ingredientmono-508-turpentine%20oil.aspx?activeingredientid=508&activeingredientname=turpentine%20oil
Gorbunov FE, Turova EA, Sichinava NV. [Changes in the functional state of the neuro-muscular apparatus in patients with distal diabetic polyneuropathies after treatment with interference currents and "yellow" turpentine baths]. Vopr Kurortol Fizioter Lech Fiz Kult 2001;6:23–7.
Davydova OB, Turova EA, Golovach AV. [The use of white and yellow turpentine baths with diabetic patients]. Vopr Kurortol Fizioter Lech Fiz Kult 1998;3:3–10.
Devi P, Madhu K, Ganapathy B, Sarma G, John L, Kulkarni C. Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy. Indian J Pharmacol 2012;44(1):51–6.
Tandan R, Lewis GA, Krusinski PB, Badger GB, Fries TJ. Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up. Diabetes Care 1992;15(1):8–14.
The Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. Arch Intern Med 1991;151(11):2225–9.
Kiania J, Ahmad Nasrollahib S, Esna-Asharic F, Fallahd P, Sajedid F. Amitriptyline 2% Cream Vs. Capsaicin 0.75% Cream in the Treatment of Painful Diabetic Neuropathy (Double Blind, Randomized Clinical Trial of Efficacy and Safety). Iranian J Pharm Res 2015;14(4):1263–8.
Published
Issue
Section
License
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
